Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

1. Mateos, M.-V.
2. Hernández, M.-T.
3. Salvador, C.
4. Rubia, J.D.L.
5. de Arriba, F.
6. López-Corral, L.
7. Rosiñol, L.
8. Paiva, B.
9. Palomera, L.
10. Bargay, J.
11. Oriol, A.
12. Prosper, F.
13. López, J.
14. Arguiñano, J.-M.
15. Bladé, J.
16. Lahuerta, J.-J.
17. San-Miguel, J.